Related references
Note: Only part of the references are listed.Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications
Lennart J. van Winden et al.
CLINICA CHIMICA ACTA (2021)
Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men Results from the MALE Phase 2 Randomized Clinical Trial
Mattea Reinisch et al.
JAMA ONCOLOGY (2021)
Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective
Huub H. van Rossum et al.
JAMA ONCOLOGY (2021)
Sex-Specific 99th Percentile Upper Reference Limits for High Sensitivity Cardiac Troponin Assays Derived Using a Universal Sample Bank
Fred S. Apple et al.
CLINICAL CHEMISTRY (2020)
Current strategies for quantification of estrogens in clinical research
Nina Denver et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer
Kohei Hashimoto et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer
Masaki Shiota et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
How low can you go? Analytical performance of five automated testosterone immunoassays
Sonia L. La'ulu et al.
CLINICAL BIOCHEMISTRY (2018)
Falsely elevated plasma testosterone concentrations in neonates: importance of LC-MS/MS measurements
Henrike M. Hamer et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2018)
Abiraterone acetate: a potential source of interference in testosterone assays
Benjamin P. Fairfax et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2018)
A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Rashid K. Sayyid et al.
CLINICAL CANCER RESEARCH (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
Discovery of LHRH and development of LHRH analogs for prostate cancer treatment
Andrew V. Schally et al.
PROSTATE (2017)
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
Laurence Klotz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction
Matthew D. Krasowski et al.
BMC CLINICAL PATHOLOGY (2014)
Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass Spectrometry
Tim M. van der Sluis et al.
JOURNAL OF UROLOGY (2012)
Total Testosterone Assays in Women with Polycystic Ovary Syndrome: Precision and Correlation with Hirsutism
Richard S. Legro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Position statement: Utility, limitations, and pitfalls in measuring testosterone: An endocrine society position statement
William Rosner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children
J Taieb et al.
CLINICAL CHEMISTRY (2003)
Share Paper
